Thus, GGDPS may serve as a more targeted approach for the treatment of both primary disease (through inhibition of Rab-mediated MM trafficking) and MM-mediated bone destruction (through inhibition of osteoclast activity). Here, AGFG1 is linked to Miyoshi myopathy.